We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Micro-RNA Prevents Liver Cancer in Mouse Model

By LabMedica International staff writers
Posted on 29 Dec 2011
A paper traced a molecular pathway in a mouse model that causes inflammation in the liver and transforms normal cells into cancerous ones.

Investigators at the Dana-Farber Cancer Institute (Boston, MA, USA) centered their study on the protein HNF4alpha (hepatocyte nuclear factor 4alpha), which is essential for liver development and hepatocyte function. More...
They examined the activity of this protein in a mouse model in which some animals were exposed to a carcinogenic chemical that causes liver cancer.

The investigators reported in the December 9, 2011, issue of the journal Cell that disruption of HNF4alpha enabled the activation of a molecular pathway comprising micro RNAs (miRNAs), interleukins, and signaling proteins. The specific molecules involved were miR-124, IL6R, STAT3, miR-24, and miR-629. Once established, this pathway became a self-sustaining inflammatory feedback loop that maintained suppression of HNF4alpha and encouraged oncogenesis.

To break the feedback loop the investigators systematically treated the animals with miR-124. This microRNA modulated inflammatory signaling with the result that is prevented, and suppressed hepatocellular carcinogenesis by inducing tumor-specific apoptosis. Treatment with miR-124 caused no toxic effects in other essential organs, such as the kidneys, spleen, heart, and lungs.

“In this study we are describing for the first time a micro-RNA that is able to prevent and treat liver cancer,” said senior author Dr. Dimitrios Iliopoulos, professor of cancer immunology at the Dana-Farber Cancer Institute. “When HNF4alpha is suppressed, it creates a temporary state of inflammation in the cell – a forerunner of cancer. After only a few days, this transient inflammatory response is converted into a chronic inflammatory response by this feedback circuit that is continuously amplified.”

“We found that miR-124 suppressed more than 80% of tumor growth and size by causing the cancer cells to self-destruct,” said Dr. Iliopoulos. “Our hope is that miR-124 potentially could be used as a preventive in patients at high risk of liver cancer because they have chronic hepatitis C or as a therapeutic agent in patients with liver cancer.”

Related Links:

Dana-Farber Cancer Institute




New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Multi-Chamber Washer-Disinfector
WD 390
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.